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Summary	
Prostate	cancers	have	a	justified	reputation	as	one	of	the	most	heterogeneous	human	
tumours.		Indeed,	there	are	some	who	consider	that	advanced	and	castration	resistant	
prostate	cancers	are	incurable,	as	a	direct	result	of	this	heterogeneity.		However,	tumour	
heterogeneity	can	be	defined	in	different	ways.		To	a	clinician,	prostate	cancer	is	a	
number	of	different	diseases,	the	treatments	for	which	remain	equally	heterogeneous	
and	uncertain.		To	the	pathologist,	the	histopathological	appearances	of	the	tumours	are	
notoriously	heterogeneous.		Indeed,	the	genius	of	Donald	Gleason	in	the	1960’s	was	to	
devise	a	classification	system	designed	to	take	into	account	the	heterogeneity	of	the	
tumours	both	individually,	and	in	the	whole-prostate	context.		To	the	cell	biologist,	a	
prostate	tumour	consists	of	multiple	epithelial	cell	types,	inter-mingled	with	various	
fibroblasts,	neuroendocrine	cells,	endothelial	cells,	macrophages	and	lymphocytes,	all	of	
which	interact	to	influence	treatment	responses	in	a	patient-specific	manner.	Finally,	
genetic	analyses	of	prostate	cancers	have	been	compromised	by	the	variable	gene	
rearrangements	and	paucity	of	activating	mutations	observed,	even	in	large	numbers	of	
patient	tumours	with	consistent	clinical	diagnoses	and/or	outcomes.		Research	into	
familial	susceptibility	has	even	generated	the	least	tractable	outcome	of	such	studies:	
the	genetic	loci	are	of	low	penetrance	and	are	of	course	heterogeneous.		By	fractionating	
the	tumor	(and	patient	matched	non-malignant	tissues)	heterogeneity	can	be	resolved,	
revealing	homogeneous	markers	of	patient	outcomes.		
	
	
Prostate	tumour	‘cells’	as	a	therapeutic	target	
Based	on	the	Gleason	histological	system	devised	in	the	1960s	(1),		imperfect	
conclusions	about	prostate	cancer	patient	outcome	can	be	made.		The	treatment	of	the	
tumor,	despite	its	frequency,	has	yet	to	be	optimized.		Studies	designed	to	decide	the	
best	early	stage	treatment	such	as	ProTect	(2)	have	provided	an	indication,	but	with	a	
long	time	scale	required	to	produce	a	decision.		It	is	however,	quite	clear	from	another	
long-term	study,	by	ERSPC	(3)	that	early	intervention,	based	on	screening		for	prostate-
specific	antigen	(PSA)	can	have	an	impact	on	death	rates,	with	the	enduring	risk	of	over-
treatment	in	the	absence	of	good	molecular	markers	for	aggressive	disease	(4).		
However,	when	primary	prostate	cancer	has	escaped	from	blockade	of	male	sex	
hormone	responses,	the	full	impact	of	heterogeneity	can	be	seen.		The	mean	survival	
times,	despite	new	generation	drugs	like	abiraterone,	apalutamide	and	enzalutamide,	
designed	to	manipulate	androgen	responsiveness	(5),	and	optimized	taxane	treatments	
which	targets	dividing	cells	(6),	remains	stubbornly	at	about	2	years	(7).		Indeed,	many	
established	treatments	from	other	tumor	types	have	only	limited	efficacy	against	
advanced	castration-resistant	prostate	cancer	(CRPC)	(8).	
	
There	are	few	simplistic	explanations	for	this	apparent	resistance.		Prostate	cancer	has,	
historically	been	considered	to	be	a	slow-growing	tumor,	yet	the	cancer	cells	cycle	at	
about	the	same	rates	as	those	from	other	tumors.		A	more	likely	explanation	comes	from	
the	observation	that	prostate	cancers	seem	to	have	a	relatively	high	intrinsic	apoptotic	
rate:	resulting	in	a	net	slower	increase	in	tumor	bulk	and	cell	numbers	(9).		If	this	is	
indeed	the	case,	then	there	is	little	justification	based	on	slower	cell	divisions	for	the	
observed	resistance	to	drugs	like	etoposide	and	docetaxel,	which	interfere	with	the	
processes	of	genome	and	cell	duplication	respectively.	
We	are	now	firmly	in	the	era	of	novel,	targeted	therapies	for	many	cancers	(including	
the	prostate),	where	genomic	information	is	rapidly	translated	into	specific	reagents	
such	as	antibodies	and	interfering	RNA,	which	can	eliminate	the	activity	of	particular	
enzymatic	targets.			The	issue	of	heterogeneity	directly	impinges	on	the	use	of	these	
targeted	reagents.		As	discussed	below,	given	the	degree	of	polymorphism	in	man,	and	
the	different	types	of	heterogeneity	seen	in	cancers,	can	one	highly	targeted	drug	ever	
be	designed	to	treat	all	patients	with	even	a	specific	grade	of	a	specific	cancer?	
	
Cellular	heterogeneities	within	a	prostate	cancer	
To	a	generation	of	cell	biologists	brought	up	on	established	cell	lines,	which	could	be	
exploited	in	controlled	growth	conditions	to	model	disease,	the	sheer	heterogeneity	of	
cell	phenotypes	present	within	a	single	cancer	can	appear	rather	daunting.		Such	
mixtures	of	cells	are	only	too	familiar	to	prostate	histopathologists,	who	have	
successively	refined	the	original	Gleason	grading	scheme	(10).			Increasingly	
multicellular	laboratory	studies	are	now	revealing	the	true	roles	played	by	the	many	cell	
types	which	affect	the	behavior	of	the	primary	tumor	cells	(secretory	epithelial	cells	for	
an	adenocarcinoma	like	prostate	cancer).		The	representations	in	Figure	1	illustrates	the	
many	cell	types	to	be	found	within	the	prostatic	normal	and	tumor	microenvironments	
(11).			
The	fate	of	the	epithelial	cells	is	intimately	linked	to	the	presence	of	the	ancillary	cells,	a	
situation	which	is	recapitulated	when	the	primary	tumor	successfully	migrates	to	a	
primary	and	secondary	metastatic	site.		Such	tumor	spread	is	frequently	associated	with	
epithelial	to	mesenchymal	transition,	a	transitory	state	in	which	a	frank	epithelial	
morphology,	and	the	gene	expression	profile	of	the	cancer	cells,	changes	to	one	
resembling	a	mesenchymal	(stem)	cell	(12).		Under	these	conditions	a	further	degree	of	
(morphological)	heterogeneity	is	observed	within	what	is	essentially	the	same	tumor	
cell	at	the	genomic	level.	
One	interesting	feature	of	the	tumor	microenvironment	is	the	extent	to	which	the	tumor	
epithelium	defines	the	phenotype	of	the	ancillary	cells	i.e.	the	development	of	a	tumor	is	
marked	by	co-evolution	of	the	primary	transformed	cell	(which	we	presume	to	be	the	
epithelial	cells	in	prostate)	perhaps	with	genetic	and	epigenetic	changes	in	the	
associated	mesenchyme	(13)	(14).	This	hypothesis	has	resulted	in	the	definition	of	
carcinoma	associated	fibroblasts	(CAFs)	as	a	discrete	cell	type	which	can	be	isolated	
from	tumor	areas.		Such	cells	have	a	more	stem	cell-like	phenotype,	and	are	capable	of	
inducing	a	carcinogenic	phenotype	in	benign	epithelial	cultures	from	prostate	such	as	
BPH1,	which	usually	form	non-malignant	cystic	growths	when	grafted	in	combination	
with	fibroblasts	from	normal	areas	of	the	prostate	(15,16).		The	mechanism	by	which	
the	benign	cultures	become	frankly	malignant	in	xenografts	is	likely	to	be	complex,	but	
there	is	good	evidence	to	suggest	that	the	TGFbeta	signaling	axis	plays	a	key	role(17).	
	
Tracking	heterogeneity	in	a	low	mutation	tumor	such	as	prostatic	
adenocarcinoma.	
Traditionally	cancer	has	been	considered	as	a	process	driven	by	mutation	in	critical	
genes,	and	an	increasing	frequency	of	mutation	detection	as	the	tumor	develops,	
including	the	development	of	resistance	to	multiple	therapies.		This	certainly	seems	to	
be	the	case	with	a	number	of	common	tumor	types	such	as	small	cell	lung	cancer	(18),	
but	prostate	cancer	belongs	to	a	low	mutation	group		(19)	(illustrated	in	Figure	2).		
Recent	next	generation	sequencing	(NGS)	of	whole	prostate	tumor	biopsy	DNA	has	
confirmed	this,	while	confirming	the	dogma	that	later	stage	cancers	(after	treatment	
failures)	carry	a	higher	mutagenic	burden	(20-22)	compared	to	treatment	naïve	
tumours.		One	paradox	in	this	data	is	the	relative	prevalence	of	both	IDH1	and	
TMPRSS2-ERG	lesions	in	early	vs	late	cancers	(22).		If	the	latter	develop	from	the	
former,	then	the	mutation	states	should	be	preserved,	as	shown	in	recent	genomic	
sequencing	studies		of	multiply	and	sequentially	biopsied	tumours	(23,24).		This	is	not	
the	case,	particularly	as	IDH1	mutations	are	undetectable	in	relapsed	cancers	(22),	
which	argues	either	for	(i)	independent	clonal	origins	for	the	relapses	–	probably	not	
correct	as	specific	mutations	are	shared	with	the	primary	tumour,	or	(ii)	that	IDH1	
mutation	confers	a	transient	advantage	to	the	early	stage	cancers,	and	that	the	relapse	
originates	in	a	less	mutated	progenitor	cell,	which	makes	up	a	small	proportion	of	the	
original	tumor	mass.	
In	terms	of	cancer	cell	survival,	mutation	can	be	considered	as	a	poor	evolutionary	step,	
particularly	in	a	changing	microenvironment	manipulated	by	successive	treatments.		
Whilst	such	non-reversible	changes	are	observed	in	genes	such	as	androgen	receptor		
(AR)	after	therapy	to	block	hormone	responses	in	prostate	cancers	(25),	there	is	
increasing	evidence	that	several	tumor	types	achieve	treatment	resistance	and	the	
evolution	of	a	fatal	metastatic	phenotype	by	means	of	epigenetic	rather	than	mutagenic	
changes.		A	good	recent	example	is	the	paucity	of		‘metastatic’	mutations	in	malignant	
pancreatic	adenocarcinoma,	where	the	tumor	evolution	is	apparently	mediated	by	
genomic	methylation	changes	(26).	
Cell	Fate	decisions	in	multicellular	prostate	tissues	
Most	studies	have	reflected	on	the	required	‘oncogenic	changes’	required	to	produce	the	
loss	of	growth	and	positional	control	which	characterize	human	cancers,	and	frequently	
used	available	cell	lines	(27)	to	define	these	changes	and	their	downstream	effects.		As	
illustrated	in	Figure	1,	a	cancer	in	man	is	a	complex	community	of	different	cell	types	
which	can	interact	with	one	another	in	positive	and	negative	ways.		However	it	is	
possible	to	generalize	about	cellular	changes	in	prostate	cancers	as	shown	in	Table	1.	
Table	1:	Some	essential	characteristics	of	Human	Prostate	Cancers	
 Tumour property (primary prostate cancers) 
1 Primary prostate cancers largely consist of replicating cells with an aberrant luminal 
phenotype (AR+, PSA secreting, changed energy requirements) whereas in normal 
tissues luminal cells rarely divide. 
2 Primary cancers have lost more than 99% of basal cells compared to normal 
prostate, where there is (in man) a contiguous basal layer lining prostatic glands. 
3 Basement membrane, which provides a barrier between the stromal and epithelial 
compartments has all but disappeared in higher grade primary cancers. 
4 The stromal compartment in cancers has a novel more embryonal phenotype (see 
above) termed ‘reactive stroma’. 
5 The intratumoral immune cell components, which include both lymphocytes and 
macrophages, undergo a distinct phenotypic switch.   
	
When	studied	at	gene	expression	or	genomic	level	using	mixed	cell	biopsies	of	tissues,	
contributions	from	minor	populations	are	masked,	and	gene	expression	from	the	most	
transcriptionally	active	cells	(secretory	luminal	cells),	which	can	be	up	to	3	logs	higher	
than	in	more	quiescent	cells,	dominates	most	gene	expression	signatures.		Of	course,	
each	biopsy	(and	patient)	has	variable	proportions	of	the	constituent	cells	which	simply	
produces	‘noise’	in	the	final	analyses	and	reduced	statistical	significance	for	the	various	
markers.		A	good	example	of	this	was	the	TCGA	attempt	using	a	combination	of	
mutations,	DNA	methylation	(at	promoters),	copy	number	alterations,	mRNA	expression	
(including	gene	fusions),	microRNA	expression	and	protein	expression	to	cluster	mixed	
cell	populations	from	333	primary	prostate	cancers,	which	left	about	26%	of	tumors	
unclassifiable	even	into	7	subtypes	(22).		Similarly,	the	expression	signature	of	highly	
secretory	immune	cells	also	contaminates	many	‘tumor	signatures’	in	blood	DNA	
classifications	(28),	whilst	stromal	cell	content	provides	the	best	indicator	of	malignancy	
in	many	colon	cancer	biopsy	studies	(29).		Such	empirical	findings	may	be	useful	in	
diagnosis,	but	the	lack	of	a	tumor	cell	component	does	not	help	in	our	understanding	of	
key	carcinogenic	changes.	
The	one	certainty	in	such	analyses	of	gene	expression,	when	cancer	biopsies	are	
compared	to	normal,	is	the	predominance	of	luminal	cell	markers	–	since	there	are	
extremely	small	numbers	of	basal	cells	in	prostate	cancers.		Indeed,	the	loss	of	
expression	of	the	strongly	basal	cell	marker	TP63	is	a	commonly	used	diagnostic	aid	to	
distinguish	benign	from	malignant	prostate	disease	(30).	
The	heterogeneity	is	also	frequently	ignored	when	the	origins	of	castration-resistant	
prostate	cancers,	and	the	ultimately	fatal	neuroendocrine	form	of	the	disease	(31)	are	
posited.		In	a	homogeneous	tumor	model,	there	is	a	requirement	for	trans-
differentiation	of	the	luminal	cancer	cells	into	CRPC	and	NE	tumours,	which	can	be	
readily	achieved	by	selection	and	treatment	of	cell	lines	such	as	LNCaP	(32,33).		
However	the	molecular	tags	of	the	relatively	rare	mutations	in	prostate	cancer	tells	
another	story.		Since	it	is	unlikely	that	cancers	can	repair	or	lose	mutations,	why	as	
discussed	earlier,	do	some	mutations	in	early	treatment	naïve	cancers,	fail	to	make	it	
into	the	CRPC	form	in	the	same	cancers?		There	are	a	number	of	mutations	(trunk	or	
founder	mutations)	which	are	conserved	–	indicative	of	a	common	cellular	origin.		We	
have	proposed	that	all	prostate	cancers	contain	a	population	of	largely	quiescent	stem-
like	or	progenitor	cells	which	are	resistant	to	most	treatments	and	provide	a	mutated	
reservoir	for	the	emergence	of	new	cancer	clones	when	the	post	treatment	
microenvironment	selects	for	a	new	variant	cell	type	(34)	(Figure	3).				Since	many	of	the	
experiments	are	carried	out	in	vitro,	it	has	been	argued	that	this	is	a	cell	culture	artifact.		
However	in	man,	an	EORTC	study	(35)	from	12	years	ago,	provided	strong	evidence	that	
the	cells	which	regrow	after	androgen	ablation	are	pre-existing	in	the	tumor	population,	
by	comparing	relapse	rates	in	2	cohorts	of	patients,	one	given	immediate	anti-androgen	
receptor	drugs,	and	a	second,	where	the	treatment	was	delayed	until	tumour	
progression	was	seen.		Realistically,	if	the	treatment	is	inducing	luminal	cancer	cells	to	
transdifferentiate,	then	the	treated	cohort	would	show	higher	and	faster	relapse.		This	
was	not	observed	in	the	trial	-	as	illustrated	in	Figure	4.	
	
Small	Non-coding	RNAs	as	controlling	factors	of	gene	expression	in	prostate	
epithelial	differentiation?	
To	establish	the	factors	which	determine	cell	phenotype	in	the	prostate,	we	have	
developed	a	fractionation	procedure	for	prostate	tissues	(36),	which	enables	both	
purification	and	ultimate	culture	of	all	cell	types,	with	the	exception	of	culturing	both	
normal	and	cancer	luminal	cells.	To	identify	the	genes	whose	expression	changes	
marked	the	epithelial	differentiation	process,	we	employed	a	pairwise	analysis	of	total	
gene	expression	patterns,	focusing	on	benign	rather	than	malignant	samples,	since	the	
benign	epithelium	had	more	consistent	expression	profiles(37).		We	reasoned	that	genes	
with	a	regulatory	role	would	change	expression	in	a	regular	manner	as	clusters.		The	
published	data	(38)	revealed	that	genes	showing	a	co-ordinate	regulation	during	
differentiation	formed	4	distinct	and	non-overlapping	sets	(Figure	5).		Overall	the	
regulatory	networks	with	the	highest	significance	in	the	transition	from	the	most	
primitive	stem	like	epithelium	to	basal	cells	committed	to	differentiation	into	luminal	
cells	were	generic	‘tissue	developmental	events’	but	more	specifically	retinoic	acid	and	
ROCK2	signalling.		Upon	the	terminal	differentiation	to	luminal	cells,	all	gene	expression	
patterns	are	dominated	by	androgen	signaling.		But	what	controls	the	switch	from	the	
basal	compartment	(where	retinoic	acid	signaling	predominates)	to	luminal	cells?		One	
clue	might	come	from	the	regulation	of	prostatic	transglutaminase(hPTG),	which	
belongs	to	one	of	the	distinct	4	transcriptional	co-regulation	groups	(39).		In	the	
upstream	control	sequences	of	hPTG,	as	in	many	other	related	genes	scattered	
throughout	the	genome,	the	binding	sites	for	the	retinoic	acid	receptor	(RAR/RXR),	are	
in	close	apposition	on	the	genome	with	those	for	AR.		However	the	RAR/RXR	sites	are	
constitutively	occupied	in	the	more	committed	basal	cells,	but	not	in	the	stem	cell	
compartment.		In	contrast,	AR	must	bind	ligand	in	the	cytoplasm	before	translocating	
into	the	nucleus	to	occupy	its	binding	sites.		The	relative	proportion	of	occupied	binding	
sites	defines	the	cell	fate	decision.	The	provision	of	activated	ligand	from	retinol	for	
RAR/RXR	is	likely	to	come	as	a	paracrine	interaction	from	the	stem/progenitor	cells	
which	constitutively	express	both	retinol	and	aldehyde	dehydrogenases,	but	very	low	
receptor	levels.	These	AR-RAR	dually	regulated	genes	mark	the	transition,	but	do	not	
effect	it	–	a	function	assigned	for	example	to	numerous	transcription	factors,	such	as	a	
master	controller	like	MYOD	in	muscle	development	(40).	
But	how	is	the	simultaneous	activation	of	transcription	factors	achieved	in	prostate?		
Hormones	clearly	provide	part	of	the	explanation,	but	in	mammalian	development,	
small	non-coding	RNAs	play	a	central	role	(41).		To	investigate	this	possibility,	we	
analysed	the	expression	patterns	of	microRNAs	in	the	fractionated	epithelial	cell	types.		
As	shown	in	Figure	6,	the	highest	expression	levels	were	seen	in	the	least	differentiated	
stem/progenitor	cells,	with	a	consistently	progressive	loss	of	expression	towards	the	
committed	basal	cells.		When	compared	to	other	cell-type	specific	miRNA	expression	
patterns	in	online	databases,	the	stem	cell	pattern	most	closely	matched	that	from	
human	embryonic	stem	cells	(42).	
However,	reflecting	the	prostatic	origin	of	the	cells,	the	benign	SC	miRNA	expression	
pattern	also	matched	that	of	total	miRNA	in	castration-resistant	prostate	cancers	(42).		
This	agrees	with	a	commonly	observed	SC-like	mRNA	gene	expression	pattern	seen	in	
CRPC	(43).		But	can	any	of	these	miRNAs	act	to	control	the	differentiation-regulating	
transcription	factors?	
Many	algorithms	have	been	developed	to	identify	the	genes	whose	expression	is	
modulated	by	a	specific	miRNA.		However,	these	are	based	on	the	theoretical	presence	of	
miRNA	recognition	sites	within	the	genome.		The	application	of	this	analysis	will	
confirm	a	miRNA	target	gene,	but	takes	no	account	of	whether	the	gene	in	question	is	
expressed	either	in	the	target	tissue,	or	indeed	the	cell	type	of	interest	within	that	tissue.		
A	classical	example	of	‘phantom’	gene	expression	control	(by	miRNA	143/145)	was	
demonstrated	in	mouse	colon	(44).	To	address	this,	a	specialized	algorithm,	which	
related	actual	mRNA	expression	in	the	prostate	epithelium	to	the	miRNA	expression	
patterns,	was	applied	(45).				This	strategy	identified	miRNA	548-3p	as	a	master	
controller	of	the	transcription	factors	implicated	in	our	earlier	studies	(RXR,	VDR,	GR,	
TAZ,	SRF,	HSF1	from	(42).		miRNA	548-3p	was	consistently	overexpressed	in	the	stem-
progenitor	population	but	not	expressed	in	the	more	committed	basal	cells.		When	
expression	was	engineered	in	the	committed	basal	cells,	the	result	was	an	increase	in	
the	stem-like	population	in	cell	cultures,	based	both	on	increased	colony	forming	
(biological)	and	the	upregulated	expression	of	a	set	of	stem/progenitor	genes	such	as	
CD49b	and	f	(integrins	alpha	2	and	6	respectively)	(42).	
During	development	of	the	expression	algorithm,	the	data	was	also	aligned	according	to	
gene	ontology	functions	in	the	differentiating	epithelium.		The	most	significant	term	was	
DNA	repair/radiation	resistance,	with	miR99a/100	as	the	most	relevant	miRNA.		
Previous	studies	had	shown	that	the	radiosensitivity	of	prostate	cell	lines	
(DU145>PC3>22RV1>LNCaP)	was	inversely	related	to	the	expression	of	miR99a/100	.		
We	had	also	demonstrated	that	the	stem-like	population	displayed	a	markedly	higher	
resistance	to	ionising	radiation	(46),	and	showed	that	this	was	a	consequence	of	the	
highly	condensed	nature	of	the	chromatin	in	the	SC.		The	induction	of	increased	
stemness	by	introduction	of	miR548-3p	into	CB	cells	also	resulted	in	an	increased	
radiation-resistance	in	the	population.			This	aligned	well	with	online	data,	which	
associated	endogenous	miR548-3p	expression	in	patients’	tumors	with	a	poorer	
prognosis	for	prostate	cancer	patients	(42).		
In	a	similar	manner,	when	the	lower	expression	of	miR99a/100	in	SC	was	engineered	by	
introduction	of	miR	inhibitors	into	the	CB	populations	and	various	established	prostate	
cell	lines,	an	increased	cell	survival,	assayed	by	colony	forming	activity	was	observed.		In	
this	case,	there	was	no	accompanying	change	in	the	differentiated	state	of	the	cells	(as	
seen	with	miR548-3p)	assayed	by	a	lack	of	expression	of	stem	cell	(NFkappaB,	ID2,	
PROM1,	SOX2)	or	EMT	(VIM,	CHDH1,	FN1)	markers.	Systematic	elimination	of	potential	
miR99a/100	target	genes,	based	on	our	algorithm	of	prostate	epithelial	mRNA	
expression	patterns,	then	identified	2	SMARC	genes	(A5	and	D1),	which	had	already	
been	assigned	a	role	in	DNA	damage	repair,	where	their	core	function	was	to	affect	
chromatin	condensation	levels,	and	to	recruit	BRCA1	and	RAD51	DNA	damage	repair	
proteins	to	radiation-induced	lesions	(47).		In	keeping	with	a	cytoprotective	property,	
upregulation	of	these	SMARC	genes	was	seen	within	3	minutes	of	prostate	epithelial	cell	
irradiation.			
There	is	also	evidence	that	cytoprotection	can	be	enhanced	by	glucocorticoids	(GC),	and	
when	SMARC	levels	were	quantified	after	dexamethasone	treatment,	they	were	also	
upregulated	by	GC.		Whilst	this	provided	a	mechanistic	proof,	it	also	implies	a	potential	
controversy	in	the	treatment	of	prostate	cancer	patients,	where	glucocorticoids	are	
historically	given	to	improve	patient	wellbeing.		This	implies	that	the	addition	of	GC	to	a	
treatment	protocol	for	radiotherapy	would	be	likely	to	compromise	the	effectiveness	of	
the	treatment.		To	test	this	hypothesis,	we	used	the	GC	response	inhibitor	mifpristerone	
which	resulted	in	an	increased	sensitivity	to	radiotherapy,	whilst	downregulating	
SMARC	expression	(47).		Thus	an	understanding	of	the	basic	biology	of	miRNA	
epigenetic	control	of	cellular	differentiation,	using	fractionated	cells	from	patient	
biopsies	could	ultimately	influence	prostate	cancer	treatment	in	patients.	
	
Methylation	of	CpG	sites	distal	from	‘CpG	islands’	as	a	genomic	control	of	
differentiation	and	carcinogenesis	in	the	prostate.	
As	discussed	earlier,	prostate	cancers	have	a	particularly	low	rate	of	carcinogenic	
mutations.		Recent	studies	of	pancreatic	cancers	(which	have	an	inherently	higher	
mutagenic	rate	than	PCa)	showed	that	epigenetic	changes	such	as	differential	genomic	
methylation	could	define	the	transition	from	organ	confined	to	malignant	cancers	(26).		
The	ability	of	methylation-editing	enzymes	to	change	global	methylation	of	CpG	and	
other	susceptible	sites	has	also	played	a	role	in	mammalian	tissue	differentiation	(48).		
In	earlier	comparisons	of	focused	methylation	within	the	promoters	of	target	genes,	we	
showed	that	the	epigenetic	modifications	in	established	cell	lines	formed	a	distinct	
cluster,	separate	from	that	in	primary	cell	cultures,	and	independent	of	pathology	
(49,50).		
To	analyse	cell-specific	methylation	patterns,	freshly	disaggregated	tissues	were	
fractionated	as	previously	described	to	generate	a	basal	fraction,	a	luminal	cell	fraction	
and	stromal	cells	(as	shown	in	figure	8A).		Using	the	relatively	conserved	tissues	from	
BPH	(37),	rather	than	cancers,	we	had	already	shown	that	even	in	primary	cultures,	
distinctive	and	functional	changes	in	gene	expression	were	induced	in	vitro	(Figure	7B).		
However	such	changes	were	limited,	compared	to	those	seen	in	a	total	gene	expression	
comparison	between	multiple	primary	epithelial	cell	cultures,	and	benign	(BPH1)	or	
malignant	(PC3)	prostate	epithelial	cell	lines	(Figure	7C).	
	After	DNA	purification	from	homogeneous	cell	fractions	(of<	1000	cells),	assayed	by	
both	RT-PCR	and	FACS	for	cancer	and	differentiation	markers	(see	Table	2),	each	DNA	
extract	was	divided,	and	one	half	was	subjected	to	bisulphite	conversion	before	
sequencing	of	both	cell	populations	{Pellacani	et	al,	in	press,	BJC	2018}	
When	subjected	to	hierarchical	clustering,	analysis	of	4	matched	human	normal:	cancer	
(defined	as	a	patient	with	a	majority	of	Gleason	Grade	4	pathology	in	the	biopsy)	pairs	of	
samples	(i.e.	6	cell	populations	resulting	in	12	datasets	per	patient).		Some	samples	from	
patient	4	were	lost	during	processing	and	only	those	with	a	high	purity	were	processed.	
	
Table	2:	Selection	and	phenotype	monitoring	of	cell	fractions	from	fresh	human	
prostate	tissues	
Cell type Selection markers Phenotype markers 
(RNA) 
Phenotype Markers 
(protein) 
Normal Basal Cells EPCAM+/CD24-/ 
CD49f+ 
KRT5/14+; TP63+ 
ITGA6+/ECAM+ 
CK5/14++ 
Normal Luminal Cells EPCAM+/CD24+/ 
CD49f- 
KRT8+/CD24+ 
EPCAM+ 
AR++/CK8+ 
Normal Stromal cells EPCAM-/CD24-/ 
CD49f- 
VIM+ VIM+/AR+ 
Cancer Basal Cells EPCAM+/CD24-/ 
CD49f+ 
AMACR+/KRT5/14+; 
TP63+/- 
CK5+: CK14+ 
ITGA6+/ECAM+ 
Cancer Luminal Cells EPCAM+/CD24+/ 
CD49f- 
AMACR++/KRT8+;  
ECAM+ 
AR++, CK8+ 
Cancer Stromal Cells EPCAM-/CD24-/ 
CD49f- 
VIM+ AR+ 
	
Initial	hierarchical	clustering	of	the	patients	based	on	their	different	CpG	methylation	
profiles	revealed	an	enhanced	ability	to	distinguish	between	patients,	regardless	of	
pathology.		In	any	multipatient	study	therefore,	this	signature	could	mask	underlying	
pathogenic-related	changes.		Secondly,	once	individual	signatures	were	removed,	a	
strong	cell-type	specific	methylation	pattern	emerged.	This	could	clearly	distinguish	
stromal	from	both	epithelial	populations,	where	signatures	were	closely	related.		When	
the	epithelial	comparisons	were	made	within	each	patient	(an	example	of	which	is	
shown	in	Figure	8A),	linking	the	methylated	CpG	to	adjacent	genes	and	their	functions,	a	
number	of	gene	ontology	terms	emerged	as	significant.		Most	changes	were	concerned	
with	basal	to	luminal	differentiation	processes,	which	was	the	original	aim	of	the	study.	
For	example,	differentially	methylated	regions	(DMRs)	in	a	comparison	of	luminal	and	
basal	cells	from	normal	prostate	epithelium	enriched	for	more	than	500	terms.		The	
hypermethylated	set	of	gene	ontology	(GO)	terms	included	many	linked	to	prostate	
development	or	epithelial	stem	cell	regulation.		The	hypomethylated	DMRs	were	
enriched	for	completely	distinct	GO	terms	principally	related	to	androgen	receptor	
signalling	and	responses	to	cytokines. 
Unlike	many	previous	studies	which	focussed	on	the	previously	determined	‘CpG	
islands’	clustered	close	to	gene	transcriptional	start	sites	(51),	we	found	that	the	most	
significantly	altered	sites	were	located	at	genomic	locations	more	than	half	of	which	fell	
outside	of	known	CpG	islands,	shores	or	shelves,	and	>70%	were	>5	kb	distant	from	
annotated	transcriptional	start	sites.	Thus,	the	differentially	hypermethylated	regions	
were	enriched	at	loci	previously	defined	as	enhancers	which	were	defined	by	three	
characteristic	properties	within	the	genomic	sequence	databases	such	as	ENCODE:	(i)	
Evolutionary	conservation	of	sequence	and	location	relative	to	the	gene	whose	
expression	is	under	enhancer	control	(ii)	Binding	sites	for	known	transcription	factors	
defined	by	chromatin	immunoprecipitation		(ChIP)	and	(iii)	The	presence	of	‘open’	
chromatin	delineated	by	DNAaseI	hypersensitivity.		The	principal	hypomethylated	loci	
included	extragenic	repetitive	sequences	such	as	LINE	and	LTR,	but	not	SINE	
repetitions.		For	example, hypermethylated enhancers were highly enriched for TFBSs of 
TP63, TP53 and NF1, and hypomethylated DMRs for FOXA1, p65-NFkB and GATA3.  A	
reassuring	differential	methylation	was	also	seen	for	2	well	established	‘epigenetically	
controlled’	genes	GSTP1	and	CCDC8,	although	this	was	characteristic	of	a	basal	to	
luminal	change	rather	than	a	cancer-specific	hypermethylation,	within	5kB	of	the	
published	transcriptional	start	sites	i.e	aligned	as	before	with	promoters	rather	than	
enhancers	(52).	
It	was	clear	from	the	data	that,	at	the	level	of	CpG	methylation,	there	were	relatively	few	
cancer-specific	methylation	changes	between	the	basal	cell	compartments	of	normal	and	
malignant	tissues	(Figure	8A).		However,	in	the	luminal	compartment,	the	differentially	
methylated	enhancer	sequences	detected	were	enriched	for	those	affecting	the	
expression	of	genes	from	the	PRC2	complex	such	as	EZH2	and	SUZ12,	previously	shown	
to	be	overexpressed	in	prostate	cancer	(53,54),	and	the	appropriate	gene	ontology	
terms	such	as	metabolic	processes,	epithelial	development	and	most	notably	cell	
proliferation.	This	agrees	with	the	major	physiological	change	between	normal	and	
cancer	luminal	cells:	normal	luminal	cells	are	terminally	differentiated	and	rarely	divide,	
whereas	the	luminal-like	cells	in	prostate	cancers	are	characterized	by	uncontrolled	cell	
division.		 
Because	the	dataset	included	patient-matched	normal:cancer	samples,	after	further	
elimination	of	cell	type-specific	changes,	we	were	able	to	assess	cancer-specific	changes	
in	the	different	cell	phenotypes	on	a	patient-by-patient	basis.		However	it	should	be	
noted	that	many	of	these	were	also	present	in	a	comparison	of	cancer	luminal	and	
cancer	basal	cells	(differentiation)	–	the	cancer	significance	was	emphasised	by	the	
absence	of	such	changes	in	a	normal	luminal-normal	basal	comparison.	Since	luminal	
cells	were	the	principal	constituent	of	the	cancer	epithelial	populations,	we	next	sought	
to	identify	cancer-specific	methylation	sites	in	comparisons	of	normal	and	malignant	
luminal	cells.		The	elimination	of	the	approximately	50%	basal	cell	content	from	the	
‘normal’	samples	ensured	that	we	did	not	rediscover	any	new	upregulated	AR	
stimulated	luminal	markers	in	these	comparisons.		
Since	our	original	discovery	sample	number	was	low	(Pellacani	et	al,	2018	in	press),	we	
sought	to	apply	the	cancer	luminal	signature	to	a	larger	number	of	cancers	from	The	
Cancer	Genome	Atlas	(TCGA)	database	which	contains	50	PCa	samples	with	matched	
normal	counterparts,	452	additional	PCa	samples	without	normal	counterparts,	and	1	
metastatic	PCa	sample.	Unfortunately	the	TCGA	data	was	generated	with	older	array	
technology,	so	the	sequence	data	was	converted	to	100bp	bins,	to	align	the	two	data	
sources.	In	the	TCGA	database,	255	array	probes	overlapped	the	1472	DMRs	we	showed	
by	sequencing	to	be	differentially	methylated	in	the	cancer	luminal	to	normal	luminal	
comparison.	When	used	to	analyse	the	matched	pairs	in	TCGA,	the	differentially	
methylated	regions	distinguished	50	cancer	from	matched	patient	normal	tissues	with	
close	to	100%	efficiency	(TPR	=	0.92,	TNR	=	0.92,	Chi-squared	test	p-value	=	2.4x10-16)	
as	shown	in	Figure	8B	(Taken	from	Pellacani	et	al,	2018,	in	press).		
Using	this	reasoning,	since	we	had	eliminated	normal	elements,	the	same	analysis	was	
carried	out	with	all	553	cancer	samples	in	the	TCGA	dataset,	resulting	in	a	similar	
outcome,	with	one	cluster	highly	enriched	in	normal	samples	(Chi-squared	test	p-value	
=	1.7x10-39).		Intriguingly,	this	clustering	also	appeared	to	divide	the	PCa	samples	into	
two	main	groups,	according	to	their	CpG	methylation	differences	from	the	normal	
samples.	Exclusive	analysis	of	the	cancer	samples	confirmed	this	clustering	pattern	and	
showed	that	one	cluster	was	significantly	enriched	for	samples	with	extra-prostatic	
extensions	(pT3	or	pT4	in	the	TNM	classification,	with	a	Chi-squared	test	p-value	<	
0.005)	in	the	absence	of	any	significant	differences	in	Gleason	score	(Chi-squared	test	p-
value	>0.1)	(Figure	8C).		
The	requirement	to	use	an	extensive	panel	of	differentially	methylated	regions	(DMRs)	
to	achieve	classification,	is	probably	an	indicator	of	the	multifactorial	and	diverse	
mechanisms	required	to	achieve	cancer	cell	malignancy.	However,	using	as	few	as	17	
DMRs	we	were	able	to	differentiate	cancer	from	normal	luminal	cell	in	data	from	mixed	
cell	biopsies	in	TCGA	with	a	92%	effectiveness	(Figures	8D&E),	indicating	that	further	
more	selective	analysis	could	result	in	an	epigenetic	differentiation	of	the	elusive	‘tiger’	
prostate	cancers	which	require	immediate	aggressive	treatment	from	the	‘pussycats’,	
which	are	best	treated	by	continuous	monitoring	rather	than	invasive	oncological	
procedures.		Since	this	was	achieved	in	routine	biopsies	of	intra-prostatic	early	stage	
disease,	implies	that	the	fate	of	a	prostate	cancer	is	programmed	into	its	genome,	not	by	
mutation	but	by	epigenetic	means	at	a	relatively	early	stage,	and	that	‘grade	progression’	
to	a	more	malignant	state,	may	exist	(55),	but	is	probably	relatively	rare	(56).	
	
Is	Epigenetic	change	the	smart	reaction	to	changing	microenvironments	in	
Prostate	Cancers?	
Our	primary	aims	in	this	research	were	to	dissect	potential	epigenetic	mechanisms	of	
gene	expression	control,	and	to	distinguish	the	changes	related	to	cellular	
differentiation,	from	those	with	a	mechanistic	importance	in	carcinogenic	change.		In	
contrast	to	most	other	studies,	our	target	materials	were	cells	taken	directly	from	
prostate	cancer	patients,	employing	the	ultimate	control:	cells	of	the	same	lineages	from	
normal	regions	of	the	same	patients’	prostates.		We	had	previously	shown	a	distinct	
difference	in	the	histone	modification	profiles,	related	to	chromatin	condensation	in	
different	cell	populations,	which	could	mark	more	undifferentiated	cells.		However,	
these	chromatin	marks	were	largely	independent	of	the	pathology	in	the	prostate.		On	a	
primary	screen,	the	same	was	largely	true	for	global	changes	in	miRNA	expression:	
which	were	first	identified	as	differentiation-linked	epigenetic	controls	(57).		However,	
as	shown	above,	a	number	of	cancer-specific	changes	were	related	to	DNA	damage	and	
repair	by	extracting	actual	gene	expression	levels,	and	matching	these	to	the	inverse	of	
changes	in	miRNA	in	the	same	cell	populations.	Both	the	ability	of	mi534	
(overexpressed	in	the	prostate	SC	population)	to	preserve	a	stem-like	state	which	was	
resistant	to	radiation	treatment	and	the	radio-protective	activity	of	low	levels	of	
miR99a/100	via	the	activation	of	SMARCs	provide	e	a	rationale	for	the	survival	of	a	
stem-like	population	after	patient	radiotherapy.		The	deleterious	effects	of	
glucocorticoid	administration,	which	is	clinically	acceptable,	may	have	to	be	
reconsidered	based	on	their	ability	to	similarly	activate	SMARCs.	
The	overall	higher	levels	of	miRNA	expression	and	the	existence	of	‘poised’	or	bivalent	
chromatin	in	the	stem-like	cells,	argues	for	an	epithelial	population	within	both	normal	
and	cancer	populations	which	is	capable	of	rapid	reaction	to	a	change	in	
microenvironment,	after	cancer	treatment	for	example.		The	emergence	of	a	stem-like	
miRNA	signature	in	the	CD133+/a2b1	high/CD44+	population,	based	on	homology	with	
not	only	human	embryonic	stem	cells	but	also	and	surprisingly	CRPC	tissues,	indicates	
that	advanced	prostate	cancers	retain	this	flexibility,	which	can	only	be	enhanced	by	the	
increased	frequency	of	mutations	in	DNA	damage	repair	genes	in	CRPC.		The	epigenetic	
ability	to	rapidly	switch	phenotype	to	a	treatment	resistant	cell	type,	which	permits	
establishment	of	permanent	resistance	after	subsequent	mutation	and	selection,	is	
entirely	consistent	with	the	development	of	drug	resistance	in	advanced	prostate	
cancers.		Since	more	cells	contain	the	stem-like	miRNA	pattern	in	the	most	advanced	
cancers,	then	the	possibilities	for	resistant	development	is	increased	as	the	tumour	
successively	escapes	from	treatments.		This	would	be	consistent	with	a	trans-
differentiation	model	in	CRPC	drug	resistance,	whereas	the	lower	content	of	stem-like	
cells	in	treatment	naïve	tumours	would	argue	for	a	stem/progenitor	origin	of	the	
resistant	population.	
Conclusion	
Prostate	cancers	are	multicellular	and	complex	in	composition.	In	scientific	attempts	to	
simplify	analysis,	we	have	adopted	a	reductionist	approach,	using	established	and	well	
characterized	cell	lines.		It	is	clear	that	with	current	comprehensive	gene	expression	
analyses,	these	basic	cell	line	tools,	established	for	more	than	40	years	in	the	laboratory,	
no	longer	represent	the	detail	in	the	actual	tumours.		The	more	we	push	their	relevance	
to	drug	response	and	tumorigenesis,	the	more	apparent	this	becomes	i.e.	apart	from	
well	characterized	hormone	responses,	translation	from	lab	to	bedside	has	been	only	
moderately	successful,	and	has	not	extended	lifespans	more	than	a	few	months	in	most	
cases.	
In	fact,	the	mere	act	of	primary	culture	induces	epigenetic	changes	which	alter	the	
expression	of	key	genes,	even	in	benign	prostate	tissues,	that	show	much	less	inter-
patient	variability	compared	to	cancers	(37).		Recent	attempts	to	classify	prostate	
cancers	according	to	clinical	outcome,	on	the	basis	of	both	genomic	and	transcriptome	
changes	have	disappointed,	even	when	biopsies	of	tumor	tissues	were	available.		For	
example,	in	the	most	comprehensive	TCGA	survey	(22)	between	a	quarter	and	a	third	of	
all	cancers	were	‘unclassified’	even	after	multiparametric	analysis.	
The	data	we	have	presented	in	this	article	argues	that	there	is	an	inherent	‘patient	
specific’	pattern	of	variation,	shown	here	at	the	epigenetic	CpG	methylation	level.		On	
top	of	this	there	is	the	cellular	composition	variation	between	tumors,	not	only	at	the	
level	of	epithelial	cell	types,	but	also	the	degree	of	stromal	cell,	and	immune	cell	content	
between	patients.		This	cannot	be	truly	represented,	even	in	mouse	models	of	the	
disease,	unless	we	can	break	heterogeneity,	by	sub-fractionating	fresh	tumors	into	their	
component	parts.		Since	most	TCGA	data	has	been	generated	from	mixed	cell	
populations,	there	is	now	a	strong	argument	in	favor	of	adopting	a	single	cell	(or	small	
homogeneous	cell	number)	approach	to	all	new	tumor	cell	analyses,	in	order	to	make	
genomics	truly	relevant	for	clinical	application.	
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Figure	and	Table	legends	
	
Figure	1	Multicellular	nature	of	normal	and	Malignant	human	prostate	tissues	
A:	Multicellular	nature	of	a	normal	prostate	acinus.		B:	Complex	multicellular	
microenvironment	of	a	malignant	prostate	gland	
Figure	2:	Prostate	cancers	contain	fewer	biologically	active	mutations	than	many	
other	common	human	tumors	
Figure	3:	Origins	of	tumor	relapses	in	prostate	cancers		
Models	are	based	on	transdifferentiation	(A)	or	regeneration	from	a	common	cancer	
stem/progenitor	cell	(B).		
Figure	4:	Similar	relapse	rates	for	prostate	cancers	after	immediate	and	deferred	
androgen	blockade		
(A)	Shows	a	selection	model	where	mutations	in	the	AR	are	induced	or	highly	selected	
compared	to	a	re-differentiation	model	from	a	stem-like	progenitor.		Original	trial	data	
showing	identical	relapse	rates	(B)	from	Studer	et	al,	2006.	
Figure	5:	Four	non-overlapping	sets	of	genes	are	co-expressed	during	
differentiation	of	prostate	epithelial	cells	
Data	from	Rane	et	al	Stem	Cell	Reports	2014	
	
Figure	6:	Patterns	of	miRNA	expression	in	fractionated	cells	from	multiple	
prostate	biopsies	
Note	the	overall	high	levels	of	miRNA	in	the	SC	compartments	where	the	expression	
profile	is	most	closely	related	to	that	found	in	human	embryonic	stem	cells	and	total	
CRPC	miRNA	patterns	of	expression.		In	keeping	with	the	differentiation-linked	
functions	of	miRNAs	a	principal	component	analysis	was	only	able	to	align	miRNA	
content	with	epithelial	cell	type,	and	not	prostate	pathology	(normal,	benign	or	
malignant)	
	
Figure	7:	Fractionation	strategy	for	primary	human	prostate	tissues		
Multiple	biopsy	strategy	and	fractionation	from	radical	prostatectomy	tissues	(A)	Gene	
expression	changes	(B)	induced	in	benign	prostate	epithelial	cell	cultures,	relative	to	
tissues	–	data	from	Rane	et	al,	2016	(C)	Gene	expression	differences	between	cell	lines	
and	primary	cell	cultures	of	prostate	epithelial	cells	(unpublished	data	from	Leanne	
Archer).		
	
Figure	8:	Epigenetic	segregation	of	normal	and	malignant	tissues	after	cell	
fractionation	to	establish	homogeneous	patterns	of	genomic	methylation	
Gene	ontology	differences	derived	from	CpG	methylation	measurements	of	fractionated	
cells	from	a	single	patient	(A).	Values	for	each	transition	refer	to	the	number	of	DMRs	
which	vary	between	each	cell	population.		Clustering	analysis	of	differentially	
methylated	sequences	using	data	from	TCGA	can	distinguish	cancer	from	normal	cells	
with	high	efficiency	(B).	Application	of	the	DMR	data	can	also	segregate	malignant	from	
organ-confined	prostate	cancers	(TCGA	data)	independently	of	the	gleason	grade	of	the	
original	cancer	(C)	and	(D/E).		A	17	locus	signature	can	be	generated	to	distinguish	
normal	from	cancer	tissues	based	solely	on	the	pattern	of	DMRs.	
Data	taken	from	Davide	Pellacani	et	al,	British	Journal	of	Cancer,	2018	(in	press)	
	
	
Table	1:	Essential	properties	of	Human	Prostate	Cancers	
Table	2:	Selection	and	phenotype	monitoring	of	cell	fractions	from	fresh	human	
prostate	tissues	
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